BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 15, Issue 12
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (3833)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.
Item 
Count 
PDF141
HTML1673
Figures (1-1)348
Tables (1-1)370
 Sum=2532
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse123
Download489
 Sum=612
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse79
Download450
 Sum=529
Dec 24, 2024 (publication date) through Oct 23, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor
Copyright ©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1520-1527
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1520
Table 1 Novel therapeutic techniques in liver cancer applications
Name
Target
Stage
Potential pros
Potential cons
PROTACs
JB170AURKAPreclinicalVersatile drug design potential; high target specificity; reduced risk of drug resistanceHigher complexity in design and development cost off-target effects; limited clinical data available
BETd-260BETPreclinical
ARV-771BRD2/3/4Preclinical
CP-10CDK6Preclinical
BSJ-03-123CDK6Preclinical
ADCs
MGC018CD276PreclinicalHigh target specificity; reduced systemic toxicityLimited scope of targetable antigens off-target effects; challenges in stability and drug release
ABBV-400METPreclinical
hYP7-DCGPC3Preclinical
CLDN6-DM1CLDN6Preclinical
mRNA vaccines
PGV002NeoantigenPhase IPersonalized treatment; potential; potential for broader; immune response; lower drug toxicPotential for immune-related; side effects; Limited clinical data in; cancer treatment
PCVNeoantigenPhase I
ABOR2014NeoantigenPhase I
PROTACs: Proteolysis-targeting chimaeras; ADCs: Antibody-coupled drugs.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345